Literature DB >> 11395034

Smoking is associated with increased hepatic lipase activity, insulin resistance, dyslipidaemia and early atherosclerosis in Type 2 diabetes.

C Kong1, L Nimmo, T Elatrozy, V Anyaoku, C Hughes, S Robinson, W Richmond, R S Elkeles.   

Abstract

We have studied the relationships between hepatic lipase activity, smoking, dyslipidaemia insulin resistance, and early atherosclerosis in 67 Type 2 diabetic subjects, 47 non-smokers and 20 smokers. Insulin resistance was measured using an insulin modified frequently sampled intravenous glucose tolerance test. Early atherosclerosis was assessed using high-resolution ultrasound to measure carotid intima media thickness (IMT) and an arterial ultrasonic score (AUS). Smokers had higher serum cholesterol and triglyceride, lower HDL and HDL2 cholesterol as well as increased hepatic lipase activity. They were also more insulin resistant than non-smokers. Smokers also had higher patient AUS scores. On multiple regression analysis, hepatic lipase activity emerged as the most significant variable affecting patient AUS. We suggest that smoking accentuates the dyslipidaemia of Type 2 diabetic subjects and this is associated with increased hepatic lipase activity. This may be one mechanism whereby smoking further increases the risk of cardiovascular disease in Type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11395034     DOI: 10.1016/s0021-9150(00)00664-x

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  33 in total

Review 1.  Hepatic lipase: friend or foe and under what circumstances?

Authors:  Hans Jansen
Journal:  Curr Atheroscler Rep       Date:  2004-09       Impact factor: 5.113

2.  Coprogression of Cardiovascular Risk Factors in Type 1 Diabetes During 30 Years of Follow-up in the DCCT/EDIC Study.

Authors: 
Journal:  Diabetes Care       Date:  2016-07-19       Impact factor: 19.112

3.  Cigarette smoking, nicotine levels and increased risk for metabolic syndrome in women with polycystic ovary syndrome.

Authors:  Cindy Ta Pau; Candace C Keefe; Corrine K Welt
Journal:  Gynecol Endocrinol       Date:  2013-06       Impact factor: 2.260

Review 4.  Principles and practice of nonpharmacological interventions to reduce cardiometabolic risk.

Authors:  Samuel Dagogo-Jack; Nonso Egbuonu; Chimaroke Edeoga
Journal:  Med Princ Pract       Date:  2010-03-29       Impact factor: 1.927

5.  Smoking is not associated with nonalcoholic fatty liver disease.

Authors:  Norberto-C Chavez-Tapia; Javier Lizardi-Cervera; Oliver Perez-Bautista; Martha H Ramos-Ostos; Misael Uribe
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

Review 6.  Metabolic effects of smoking cessation.

Authors:  Kindred K Harris; Mohan Zopey; Theodore C Friedman
Journal:  Nat Rev Endocrinol       Date:  2016-03-04       Impact factor: 43.330

7.  Glucoregulation has greater impact on cognitive performance than macro-vascular disease in men with type 2 diabetes: data from the Caerphilly study.

Authors:  John E J Gallacher; Janet Pickering; Peter C Elwood; Anthony J Bayer; John W Yarnell; Yoav Ben-Shlomo
Journal:  Eur J Epidemiol       Date:  2005       Impact factor: 8.082

8.  Relationship between metabolic syndrome and familial history of hypertension/stroke, diabetes, and cardiovascular disease.

Authors:  Kyung Won Paek; Ki Hong Chun; Kwan Woo Lee
Journal:  J Korean Med Sci       Date:  2006-08       Impact factor: 2.153

9.  Prevalence of metabolic syndrome and associated risk factors among Turkish adults: Trabzon MetS study.

Authors:  Cihangir Erem; Arif Hacihasanoglu; Orhan Deger; Murat Topbaş; Ilgin Hosver; Halil Onder Ersoz; Gamze Can
Journal:  Endocrine       Date:  2008-03-13       Impact factor: 3.633

10.  The prevalence of pre-hypertension and hypertension in an Iranian urban population.

Authors:  Ahmad Khosravi; Mohammad Hassan Emamian; Mohammad Shariati; Hassan Hashemi; Akbar Fotouhi
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.